Original paper
Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses
Abstract
Background null The primary APACT analysis showed no significant difference in disease-free survival (DFS) by blinded, independent radiologic review with nab-P/G vs G in patients (pts) with surgically resected pancreatic cancer (PC). However, investigator-assessed DFS (prespecified sensitivity analysis) and interim overall survival (OS; secondary endpoint) trended in favor of nab-P/G. Here, we report interim OS exploratory subanalyses. null null...
Paper Details
Title
Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses
Published Date
Oct 1, 2019
Journal
Volume
30
Pages
v259 - v260
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History